Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Next-Generation Sequencing in Medicine (Upcoming)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Receptors for prostaglandin E2 that regulate cellular immune responses in the mouse
Chandra Nataraj, … , Beverly H. Koller, Thomas M. Coffman
Chandra Nataraj, … , Beverly H. Koller, Thomas M. Coffman
Published October 15, 2001
Citation Information: J Clin Invest. 2001;108(8):1229-1235. https://doi.org/10.1172/JCI13640.
View: Text | PDF
Article

Receptors for prostaglandin E2 that regulate cellular immune responses in the mouse

  • Text
  • PDF
Abstract

Production of prostaglandin E2 (PGE2) is enhanced during inflammation, and this lipid mediator can dramatically modulate immune responses. There are four receptors for PGE2 (EP1–EP4) with unique patterns of expression and different coupling to intracellular signaling pathways. To identify the EP receptors that regulate cellular immune responses, we used mouse lines in which the genes encoding each of the four EP receptors were disrupted by gene targeting. Using the mixed lymphocyte response (MLR) as a model cellular immune response, we confirmed that PGE2 has potent antiproliferative effects on wild-type responder cells. The absence of either the EP1 or EP3 receptors did not alter the inhibitory response to PGE2 in the MLR. In contrast, when responder cells lacked the EP2 receptor, PGE2 had little effect on proliferation. Modest resistance to PGE2 was also observed in EP4–/– responder cells. Reconstitution experiments suggest that EP2 receptors primarily inhibit the MLR through direct actions on T cells. Furthermore, PGE2 modulates macrophage function by activating the EP4 receptor and thereby inhibiting cytokine release. Thus, PGE2 regulates cellular immune responses through distinct EP receptors on different immune cell populations: EP2 receptors directly inhibit T cell proliferation while EP2 and EP4 receptors regulate antigen presenting cells functions.

Authors

Chandra Nataraj, Dennis W. Thomas, Stephen L. Tilley, MyTrang Nguyen, Roslyn Mannon, Beverly H. Koller, Thomas M. Coffman

×

Figure 4

Options: View larger image (or click on image) Download as PowerPoint
Comparison of PGE2 effects on allospecific proliferation of EP2-deficien...
Comparison of PGE2 effects on allospecific proliferation of EP2-deficient mixed splenocytes and T cells. MLR experiments were performed comparing responders that were lacking EP2 receptors (filled bars) with their respective wild-type controls (open bars). Responder cells were either unseparated populations of mixed splenocytes (left) or T cells that had been purified from the spleen (right). Allospecific proliferation was measured in the presence of 30 nM PGE2 or vehicle. The data are expressed as percentage of inhibition compared with the MLR with vehicle alone. *P < 0.001 vs. EP2+/+.

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts